<!DOCTYPE html>
<html lang="en">
	<head>
  		<meta charset="UTF-8">
  		<title>Bio2RDF - Drugbank</title>
		<link href="images/bio2rdf.png" rel="shortcut icon" />
		<link rel="stylesheet" type="text/css" href="css/style.css" media="screen" />
  		<script src="https://code.jquery.com/jquery-3.2.1.min.js"></script>
  		<script src="handlebars-v4.0.10.js"></script>
  		<!--<script src="https://cdnjs.cloudflare.com/ajax/libs/handlebars.js/4.0.10/handlebars.runtime.min.js"></script>-->
	
		<script type="application/ld+json">{
 "@context" : "http://schema.org",
  "id" : "http://bio2rdf.org/drugbank:DB00022",
  "type" : "Drug",
  "administrationRoute" : "subcutaneous",
  "availableStrength" : [ {
    "id" : "http://bio2rdf.org/drugbank_resource:2bf994861540f24a8722eb8a3c6fee12",
    "type" : "DrugStrength",
    "description" : "120 ug/.5mL Injection, powder, lyophilized, for solution form with subcutaneous route"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:b29f89bee93e1e594b575af4821c8261",
    "type" : "DrugStrength",
    "description" : "50 ug/.5mL Injection, powder, lyophilized, for solution form with subcutaneous route"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:b255400f9f7b73710df1af7f3b7bc72a",
    "type" : "DrugStrength",
    "description" : "150 ug/.5mL Injection, powder, lyophilized, for solution form with subcutaneous route"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:4ab8cecf91190bcca217cad031aebb3d",
    "type" : "DrugStrength",
    "description" : "80 ug/.5mL Injection, powder, lyophilized, for solution form with subcutaneous route"
  } ],
  "clinicalPharmacology" : "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.",
  "cost" : [ {
    "id" : "http://bio2rdf.org/drugbank_resource:58e0afb9d22ca29e0a14e9cf648feaa1",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "2428.800048828125",
    "drugUnit" : "Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:5860d834a1c62569a3ec7a6f751012c8",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "553.4000244140625",
    "drugUnit" : "Peg-Intron 50 mcg kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:51cd037590f0e859e9c7ace56015cdf1",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "669.3900146484375",
    "drugUnit" : "Peg-Intron Redipen 120 mcg/0.5ml Kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:b6d705bdfed50f0aba880d42c2652432",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "702.8699951171875",
    "drugUnit" : "Peg-Intron Redipen 150 mcg/0.5ml Kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:aa905724f387564be3a66e70585a8d97",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "640.5999755859375",
    "drugUnit" : "Peg-Intron redipen 150 mcg 4pk"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:8074850bd60769b1f69eec3651067df6",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "553.4000244140625",
    "drugUnit" : "Peg-Intron redipen 50 mcg"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:1ce1291bac3aefe00fd4d4990a113ffc",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "610.09002685546875",
    "drugUnit" : "Peg-Intron redipen 120 mcg"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:fe02808d522a1143c893d0aff950fae0",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "671.739990234375",
    "drugUnit" : "Peg-Intron 150 mcg Kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:f7abab7cff268a32b2c112db6e9ea4ec",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "640.6099853515625",
    "drugUnit" : "Peg-Intron redipen 150 mcg"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:75e6d5c4ecb9f78fe632b611d324ca0d",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "637.489990234375",
    "drugUnit" : "Peg-Intron Redipen 80 mcg/0.5ml Kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:f7ddd5427b7c166a230b2bf99828551a",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "607.19000244140625",
    "drugUnit" : "Peg-Intron 50 mcg/0.5ml Kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:f5b6b5b7da1d4c0f21f3ac460c4ef5fa",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "639.739990234375",
    "drugUnit" : "Peg-Intron 120 mcg Kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:42d86cdb921f68fc434ac02d44387f24",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "609.260009765625",
    "drugUnit" : "Peg-Intron 80 mcg Kit"
  }, {
    "id" : "http://bio2rdf.org/drugbank_resource:ece23d55568339034ee7206279ef3026",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "581.02001953125",
    "drugUnit" : "Peg-Intron redipen 80 mcg"
  } ],
  "description" : "Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of <i>Escherichia coli</i> bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.",
  "dosageForm" : "Injection, powder, lyophilized, for solution",
  "drugClass" : "Immunosuppressive Agents",
  "schema:identifier" : "drugbank:DB00022",
  "interactingDrug" : [ "DDI between Peginterferon alfa-2b and Pimozide - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Flecainide - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Mirtazapine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Perphenazine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Venlafaxine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Ropivacaine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Haloperidol - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Clozapine - Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.", "DDI between Peginterferon alfa-2b and Fluoxetine - Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine.", "DDI between Peginterferon alfa-2b and Duloxetine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Mexiletine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Acenocoumarol - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Thiothixene - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Clomipramine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Ramelteon - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Gefitinib - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Eliglustat - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Rasagiline - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Procainamide - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Methadone - Interferons (Alfa) may increase the serum concentration of Methadone.", "DDI between Peginterferon alfa-2b and Bromazepam - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Caffeine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Alosetron - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Olanzapine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Metoprolol - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Pipotiazine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Tamoxifen - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Paroxetine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Asenapine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Tizanidine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Theophylline - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Dextromethorphan - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Amitriptyline - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Thioridazine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Maprotiline - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Carvedilol - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Atomoxetine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Imipramine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Cyclobenzaprine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Chlorphenamine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Dihydrocodeine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Nortriptyline - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Amoxapine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Captopril - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Timolol - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Procaine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Promazine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Dacarbazine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Risperidone - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Propranolol - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Primaquine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Zuclopenthixol - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Trifluoperazine - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Methamphetamine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Ribavirin - Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.", "DDI between Peginterferon alfa-2b and Telbivudine - Peginterferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.", "DDI between Peginterferon alfa-2b and Trimipramine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Tolterodine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Flutamide - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Chlorpromazine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Aripiprazole - CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.", "DDI between Peginterferon alfa-2b and Aldesleukin - Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.", "DDI between Peginterferon alfa-2b and Tetrabenazine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Nefazodone - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Ropinirole - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Protriptyline - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Chloroquine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Pomalidomide - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Zidovudine - Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.", "DDI between Peginterferon alfa-2b and Promethazine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Isometheptene - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Betaxolol - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Desipramine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Fluvoxamine - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates.", "DDI between Peginterferon alfa-2b and Aminophylline - May increase the serum concentration of CYP1A2 Substrates.", "DDI between Peginterferon alfa-2b and Iloperidone - May decrease the serum concentration of CYP2D6 Substrates. Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates." ],
  "legalStatus" : "Approved",
  "mechanismOfAction" : "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.",
  "name" : "Peginterferon alfa-2b",
  "proprietaryName" : "PEG-Intron",
  "sameAs" : [ "http://www.drugs.com/cdi/peginterferon-alfa-2b.html", "http://www.drugbank.ca/drugs/DB00022", "http://www.rxlist.com/cgi/generic2/peginterferon.htm" ],
  "schema:url" : "http://bio2rdf.org/drugbank:DB00022"
}</script>
	</head>

	<body>
		<br/><br/>
		
		<div id="all">
	 		<div id="main" style="text-align: center;">
	 			<div style="height: 20%;">&nbsp;</div>
	 			<img alt="Drugbank" src="images/drugbank.png" />
	 			<div id="main" style="text-align: center;">
	 				<em>Bio2RDF Drugbank Data</em>
				</div>

				<br/><br/>

			</div>

			<div id="contents">
				<script type="text/javascript">

				var templateCode = "<table><tbody><tr><td class='dataframeKey'>Drug Name</td><td>{{name}}</td></tr><tr><td class='dataframeKey'>Description</td><td>{{description}}</td></tr><tr><td class='dataframeKey'>Identifier</td><td>{{schema:identifier}}</td></tr><tr><td class='dataframeKey'>Non-Proprietary Names</td><td><ul>{{#each nonProprietaryName}}<li>{{this}}</li>{{else}}{{nonProprietaryName}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Proprietary Name</td><td>{{proprietaryName}}</td></tr><tr><td class='dataframeKey'>Drug Classes</td><td><ul>{{#each drugClass}}<li>{{this}}</li>{{else}}{{drugClass}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Clinical Pharmacology</td><td>{{clinicalPharmacology}}</td></tr><tr><td class='dataframeKey'>Manufacturer</td><td>{{#with manufacturer}}{{name}}{{/with}}</td></tr><tr><td class='dataframeKey'>Mechanism of Action</td><td>{{mechanismOfAction}}</td></tr><tr><td class='dataframeKey'>Food Warning</td><td>{{foodWarning}}</td></tr><tr><td class='dataframeKey'>URL</td><td><a href='{{schema:url}}'>{{schema:url}}</a></td></tr><tr><td class='dataframeKey'>Costs</td><td>{{#if cost.length}}<ul>{{#each cost}}<li>{{#with this}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}</li>{{/each}}</ul>{{else}}{{#with cost}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Available Strength</td><td>{{#if availableStrength.length}}<ul>{{#each availableStrength}}<li>{{this.description}}</li>{{/each}}</ul>{{else}}{{#with availableStrength}}{{description}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Dosage Forms</td><td><ul>{{#each dosageForm}}<li>{{this}}</li>{{else}}{{dosageForm}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Administration Route</td><td><ul>{{#each administrationRoute}}<li>{{this}}</li>{{else}}{{administrationRoute}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Interacting Drugs</td><td><ul>{{#each interactingDrug}}<li>{{this}}</li>{{else}}{{interactingDrug}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Legal Statuses</td><td><ul>{{#each legalStatus}}<li>{{this}}</li>{{else}}{{legalStatus}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Same As</td><td><ul>{{#each sameAs}}<li><a href='{{this}}'>{{this}}</a></li>{{else}}<a href='{{sameAs}}'>{{sameAs}}</a>{{/each}}</ul></td></tr></tbody></table>";
				var template = Handlebars.compile(templateCode);

				$.getJSON("jsonld/DB00022.json", function(data) {
			    	document.getElementById("contents").innerHTML += template(data);
				});
		
				</script>
			</div>
		</div>
	</body>
</html>